Management of COPD patients during COVID: difficulties and experiences

References

• Sin DD. COVID-19 in COPD: a growing concern. EClinicalMedicine. 2020;26:100546.
   PubMedGoogle Scholar
• Halpin DMG, Criner GJ, Papi A, et al., Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 203(1): 24–36. 2021.
   PubMed Web of Science ®Google Scholar
• Rabbani G, Shariful Islam SM, Rahman MA, et al. Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis. Expert Rev Respir Med. 2021;15(5):705–716.
   PubMed Web of Science ®Google Scholar
• Shastri MD, Shukla SD, Chong WC, et al. Smoking and COVID-19: what we know so far. Respir Med. 2020;176:106237.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tobacco users may be at an increased risk of #COVID19, both in Contracting the Disease and Complications. [cited 2020 Dec 22]. Available from: https://twitter.com/WHO_Europe/status/1257255102634745857
   Google Scholar
• Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317.
   PubMed Web of Science ®Google Scholar
• Smith JC, Sausville EL, Girish V, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell. 2020;53(5):514–529.
   PubMed Web of Science ®Google Scholar
• Scialo F, Daniele A, Amato F, et al., ACE2: the major cell entry receptor for SARS-CoV-2. Lung. 198(6): 867–877. 2020.
   PubMed Web of Science ®Google Scholar
• Tomchaney M, Contoli M, Mayo J, et al. Paradoxical effects of cigarette smoke and COPD on SARS-CoV2 infection and disease. bioRxiv. 2020. 10.1101/2020.12.07.413252.. Preprint.
   PubMedGoogle Scholar
• González-Rubio J, Navarro-López C, López-Nájera E, et al. A systematic review and meta-analysis of hospitalised current smokers and COVID-19. Int J Environ Res Public Health. 2020;17(20):7394.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, et al. Cytokine release syndrome (CRS) and nicotine in COVID-19 patients: trying to calm the storm. Front Immunol. 2020;11:1359.
   PubMed Web of Science ®Google Scholar
• Bevelacqua JJ, Masoompour SM, Mortazavi SAR, et al. Why do some reports claim that the number of COVID-19 hospitalized smokers is smaller than expected? J Biomed Phys Eng. 2020;10(5):659–662.
   PubMedGoogle Scholar
• Patanavanich R, Glantz SA. Smoking Is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;22(9):1653–1656.
   PubMed Web of Science ®Google Scholar
• Liu A, Zhang X, Li R, et al. Overexpression of the SARS-CoV-2 receptor ACE2 is induced by cigarette smoke in bronchial and alveolar epithelia. J Pathol. 2021;253(1):17–30.
   PubMed Web of Science ®Google Scholar
• Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):2000688.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.
   PubMed Web of Science ®Google Scholar
• Saheb Sharif-Askari N, Saheb Sharif-Askari F, Alabed M, et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol Ther Methods Clin Dev. 2020;18:1–6.
   PubMed Web of Science ®Google Scholar
• Yin J, Kasper B, Petersen F, et al. Association of cigarette smoking, COPD, and lung cancer with expression of SARS-CoV-2 entry genes in human airway epithelial cells. Front Med. 2020;7:619453.
   Web of Science ®Google Scholar
• Hsu AC, Parsons K, Moheimani F, et al. Impaired antiviral stress granule and IFN-β enhanceosome formation enhances susceptibility to Influenza Infection in chronic obstructive pulmonary disease epithelium. Am J Respir Cell Mol Biol. 2016;55(1):117–127.
   PubMed Web of Science ®Google Scholar
• Higham A, Mathioudakis A, Vestbo J, et al., COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. Eur Respir Rev. 29(158): 200199. 2020.
   PubMed Web of Science ®Google Scholar
• Sharma P, Pandey AK, Bhattacharyya DK. Determining crucial genes associated with COVID-19 based on COPD findings. Comput Biol Med. 2021;128:104126.
   PubMed Web of Science ®Google Scholar
• Dong W, Zhu Y, Du Y, et al. Association between features of COPD and risk of venous thromboembolism. Clin Respir J. 2019;13(8):499–504.
   PubMed Web of Science ®Google Scholar
• Dobesh PP, Trujillo TC. Coagulopathy, venous thromboembolism, and anticoagulation in patients with COVID-19. Pharmacotherapy. 2020;40(11):1130–1151.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al., COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 75(23): 2950–2973. 2020.
   PubMed Web of Science ®Google Scholar
• Attaway A, Hatipoğlu U. Management of patients with COPD during the COVID-19 pandemic. Cleve Clin J Med. 2020. 10.3949/ccjm.87a.ccc007.
   PubMed Web of Science ®Google Scholar
• Simons SO, Hurst JR, Miravitlles M, et al., Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. Thorax. 75(12): 1035–1039. 2020.
   PubMed Web of Science ®Google Scholar
• Hu W, Dong M, Xiong M, et al. Clinical courses and outcomes of patients with chronic obstructive pulmonary disease during the COVID-19 epidemic in Hubei, China. Int J Chron Obstruct Pulmon Dis. 2020;15:2237–2248.
   PubMed Web of Science ®Google Scholar
• Chan KPF, Ma TF, Kwok WC, et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med. 2020;171:106085.
   PubMed Web of Science ®Google Scholar
• Tan JY, Conceicao EP, Wee LE, et al. COVID-19 public health measures: a reduction in hospital admissions for COPD exacerbations. Thorax. 2020. DOI: 10.1136/thoraxjnl-2020-216083.
   Web of Science ®Google Scholar
• Tal-Singer R, Crapo JD. COPD at the time of COVID-19: a COPD Foundation perspective. Chronic Obstr Pulm Dis. 2020;7(2):73–75.
   PubMed Web of Science ®Google Scholar
• Pleguezuelos E, Del Carmen A, Moreno E, et al. <p>The experience of COPD patients in lockdown due to the COVID-19 pandemic. Int J Chron Obstruct Pulmon Dis. 2020;15:2621–2627.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhou Y, Wang Z, et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study. J Thorac Dis. 2020;12(5):1811–1823.
   PubMed Web of Science ®Google Scholar
• Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.
   PubMed Web of Science ®Google Scholar
• Attaway AA, Zein J, Hatipoğlu US. SARS-CoV-2 infection in the COPD population is associated with increased healthcare utilization: an analysis of Cleveland clinic’s COVID-19 registry. EClinicalMedicine. 2020;26:100515.
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. GOLD COVID-19 guidance. [cited 2020 Dec 22]. Available from: https://goldcopd.org/gold-covid-19-guidance/
   Google Scholar
• Bhutani M, Hernandez P, Bourbeau J, et al. Addressing therapeutic questions to help Canadian health care professionals optimize COPD management for their patients during the COVID-19 pandemic. Can Respir, Crit Care, and Sleep Med. 2020;4(2):77–80.
   Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Stolz D, et al. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8:F1000. Faculty Rev–1533
   PubMedGoogle Scholar
• Vasanthakumar N. Can beta-adrenergic blockers be used in the treatment of COVID-19? Med Hypotheses. 2020;142:109809.
   PubMed Web of Science ®Google Scholar
• Elbeddini A, Tayefehchamani Y, Yang L. Strategies to conserve salbutamol pressurized metered-dose inhaler stock levels amid COVID-19 drug shortage. Drugs Ther Perspect. 2020. DOI:10.1007/s40267-020-00759-1.
   Google Scholar
• Elbeddini A, Yeats A. Amid COVID-19 drug shortages: proposed plan for reprocessing and reusing salbutamol pressurized metered dose inhalers (pMDIs) for shared use. Drugs Ther Perspect. 2020. 10.1007/s40267-020-00740-y.
   Google Scholar
• Beck BR, Shin B, Choi Y, et al. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784–790.
   PubMed Web of Science ®Google Scholar
• Sarma P, Shekhar N, Prajapat M, et al. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn. 2020. 10.1080/07391102.2020.1753580.
   PubMed Web of Science ®Google Scholar
• Choi JC, Jung SY, Yoon UA, et al. Inhaled corticosteroids and COVID-19 risk and mortality: a nationwide cohort study. J Clin Med. 2020;9(11):3406.
   Web of Science ®Google Scholar
• Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol. 2020;147(2):510–519.e5.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Lauro D, Di Daniele N, et al. Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids? Expert Rev Respir Med. 2020. 10.1080/17476348.2021.1850275..
   Web of Science ®Google Scholar
• Schultze A, Walker AJ, MacKenna B, et al., Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 8(11): 1106–1120. 2020.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;55(5):2001009.
   PubMed Web of Science ®Google Scholar
• Ari A. Use of aerosolised medications at home for COVID-19. Lancet Respir Med. 2020;8(8):754–756.
   PubMedGoogle Scholar
• Sockrider M, Tal-Singer R. Managing your chronic lung disease during the COVID-19 pandemic. Am J Respir Crit Care Med. 2020;202(2):P5–6.
   Google Scholar
• Cazzola M, Ora J, Bianco A, et al. Guidance on nebulization during the current COVID-19 pandemic. Respir Med. 2020;176:106236.
   PubMed Web of Science ®Google Scholar
• Shah CA. Can roflumilast become steroid-sparing alternative in the treatment of COVID-19? Med Hypotheses. 2020;144:110246.
   PubMed Web of Science ®Google Scholar
• Sharma G, Champalal Sharma D, Hwei Fen L, et al. Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor. Emerg Microbes Infect. 2013;2(1):e54.
   PubMedGoogle Scholar
• Hu F, Jiang J, Yin P. Prediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep model. arXiv Preprint. 2020;arXiv:2003.00728.
   Google Scholar
• Cui Y, Luo L, Li C, et al. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3813–3829.
   PubMed Web of Science ®Google Scholar
• Qiu S, Zhong X. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2017;128(3):147–155.
   Google Scholar
• Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2020. 10.1080/14787210.2020.1813024..
   Web of Science ®Google Scholar
• Bakadia BM, He F, Souho T, et al. Prevention and treatment of COVID-19: focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomed Pharmacother. 2021;133:111008.
   PubMed Web of Science ®Google Scholar
• Poschet JF, Perkett EA, Timmins GS, et al. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. bioRxiv. 2020. 10.1101/2020.03.29.008631.. Preprint.
   PubMedGoogle Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
   PubMed Web of Science ®Google Scholar
• Lighter J, Raabe V. Azithromycin should not be used to treat COVID-19. Open Forum Infect Dis. 2020;7(6):ofaa207.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Page C, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20(1):104.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Page C, et al. Thiol-based drugs in pulmonary medicine: much more than mucolytics. Trends Pharmacol Sci. 2019;40(7):452–463.
   PubMed Web of Science ®Google Scholar
• De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J. 2020;34(10):13185–13193.
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2021;384(8):693–704.
   Web of Science ®Google Scholar
• Inoue H, Jinno M, Ohta S, et al. Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD. Respiratory Medicine Case reports. 2020;31:101200.
   PubMed Web of Science ®Google Scholar
• Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166(3):949–954.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Gibbons CL, Cooper L, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020;15(6):952–960.
   Google Scholar
• Shi Z, Puyo CA. <p>N-Acetylcysteine to Combat COVID-19: an evidence review. Ther Clin Risk Manag. 2020;16:1047–1055.
   PubMed Web of Science ®Google Scholar
• Clini EM, Ambrosino N. Nonpharmacological treatment and relief of symptoms in COPD. Eur Respir J. 2008;32(1):218–228.
   PubMed Web of Science ®Google Scholar
• Corn J, Malanga E, Pruitt K. What to do when pulmonary rehabilitation (PR) is unavailable. Am J Respir Crit Care Med. 2020;201(11):PP25–26.
   Web of Science ®Google Scholar
• Bourne S, DeVos R, North M, et al. Online versus face-to-face pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: randomised controlled trial. BMJ Open. 2017;7(7):e014580.
   PubMed Web of Science ®Google Scholar
• Demoule A, Vieillard Baron A, Darmon M, et al., High-flow nasal cannula in critically iII patients with severe COVID-19. Am J Respir Crit Care Med. 202(7): 1039–1042. 2020.
   PubMed Web of Science ®Google Scholar
• Lim ZJ, Subramaniam A, Ponnapa Reddy M, et al. Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. A meta-analysis. Am J Respir Crit Care Med. 2021;203(1):54–66.
   PubMed Web of Science ®Google Scholar
• De Blasio F, Di Gregorio A, De Blasio F, et al. Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables. Respir Med. 2018;134:1–5.
   PubMed Web of Science ®Google Scholar
• Barazzoni R, Bischoff SC, Breda J, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020;176(6):1631–1638.
   Google Scholar
• Kouri A, Gupta S, Yadollahi A, et al. Addressing reduced laboratory-based pulmonary function testing during a pandemic. Chest. 2020;158(6):2502–2510.
   PubMed Web of Science ®Google Scholar
• Task force of pulmonary function testing and clinical respiratory physiology, Chinese association of chest physicians; pulmonary function testing group, respiratory therapeutics group, Chinese thoracic society. Expert consensus on pulmonary function testing during the epidemic of coronavirus disease [Article in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(4):302-307.
   Google Scholar
• Hull JH, Lloyd JK, Cooper BG. Lung function testing in the COVID-19 endemic. Lancet Respir Med. 2020;8(7):666–667.
   PubMed Web of Science ®Google Scholar
• Segreti A, Stirpe E, Rogliani P, et al. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther. 2014;18(4):381–388.
   PubMed Web of Science ®Google Scholar
• Lee AC, Chakladar J, Li WT, et al. Tobacco, but not nicotine and flavor-less electronic cigarettes, induces ACE2 and immune dysregulation. Int J Mol Sci. 2020;21(15):5513.
   Web of Science ®Google Scholar
• Tang XJ, Xi XH, Chen CC, et al. Long-term follow-up of 5 survivors after the first outbreak of human infections with avian influenza A(H7N9) virus in Shanghai, China. Chin Med J (Engl). 2016;129(17):2128–2130.
   PubMed Web of Science ®Google Scholar
• Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8(1):8.
   PubMed Web of Science ®Google Scholar
• Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
   PubMedGoogle Scholar
• Figueira Gonçalves JM, Golpe R. Retos clínicos en pacientes con enfermedad pulmonar obstructiva crónica que han sufrido una infección por SARS-CoV-2. Med Clin (Barc). 2020;155(4):162–164.
   PubMedGoogle Scholar
• Figueira Gonçalves JM, García-Talavera I, Golpe R, et al. [Post-COVID syndrome in the patient with chronic obstructive pulmonary disease: a Trojan horse?]. Semergen. 2020;47(2):136–137.
   PubMedGoogle Scholar
• Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542–2020.
   PubMedGoogle Scholar